Crossmark

Design matters in patient-level prediction: evaluation of a cohort vs. case-control design when developing predictive models in observational healthcare datasets

Crossref DOI link: https://doi.org/10.1186/s40537-021-00501-2

Published Online: 2021-08-16

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Reps, Jenna M. http://orcid.org/0000-0002-2970-0778
Ryan, Patrick B.

Rijnbeek, Peter R.

Schuemie, Martijn J.
Funding

Funding for this research was provided by:

Innovative Medicines Initiative (806968)
License Information

Text and Data Mining valid from 2021-08-16

Version of Record valid from 2021-08-16
More Information

Article History

Received: 18 March 2021

Accepted: 8 August 2021

First Online: 16 August 2021

Declarations

:

: The use of Optum Claims was reviewed by the New England Institutional Review Board (IRB) and were determined to be exempt from broad IRB approval.

: Not applicable.

: JMR, PBR and MJS are employees of Janssen R&D and shareholders of Johnson and Johnson.

Document is current

Any future updates will be listed below